| Title |
TMA secondary to SLE: rituximab improves overall but not renal survival
|
|---|---|
| Published in |
Clinical Rheumatology, August 2017
|
| DOI | 10.1007/s10067-017-3793-4 |
| Pubmed ID | |
| Authors |
Fangfang Sun, Xiaodong Wang, Wanlong Wu, Kaiwen Wang, Zhiwei Chen, Ting Li, Shuang Ye |
| Abstract |
Thrombotic microangiopathy (TMA) includes a series of life-threatening disorders. Systemic lupus erythematosus (SLE) is one of the most common acquired causes. To identify predictors of prognosis in patients with TMA secondary to SLE, we conducted a single-center historical study. From January 2013 to June 2016, of 2182 SLE hospitalized patients in the Ren Ji Hospital, a total of 21 consecutive patients with TMA secondary to SLE were identified. The 90-day short-term mortality was 33.3%. The kidney involvement (66.7%) was associated with poor prognosis, while the administration of rituximab (n = 13) was an independent protective factor according to logistic regression analysis. Compared to conventional treatment, i.e., plasma exchange, high-dose glucocorticoids, and intravenous immunoglobulin, the overall survival is significantly higher among patients receiving rituximab add-on (92.2 vs 33.3%, p = 0.0173); however, five out of seven patients with renal involvement in the rituximab group were eventually hemodialysis dependent. Our data indicated that add-on rituximab in the background of conventional therapy may improve the overall but not the renal survival in SLE-TMA patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 9% |
| Student > Doctoral Student | 2 | 9% |
| Student > Master | 2 | 9% |
| Professor | 2 | 9% |
| Student > Postgraduate | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 10 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Chemistry | 1 | 5% |
| Materials Science | 1 | 5% |
| Unknown | 11 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2019.
All research outputs
#20,449,496
of 23,005,189 outputs
Outputs from Clinical Rheumatology
#2,664
of 3,041 outputs
Outputs of similar age
#275,673
of 315,734 outputs
Outputs of similar age from Clinical Rheumatology
#52
of 65 outputs
Altmetric has tracked 23,005,189 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,041 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,734 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.